Takeda Pharmaceutical Valuation
| TAK Stock | USD 18.66 0.12 0.65% |
At this time, the company appears to be fairly valued. Takeda Pharmaceutical has a current Real Value of $18.21 per share. The regular price of the company is $18.66. Our model measures the value of Takeda Pharmaceutical from inspecting the company fundamentals such as Return On Equity of 0.015, shares outstanding of 3.16 B, and Operating Margin of 0.11 % as well as reviewing its technical indicators and probability of bankruptcy.
Price Book 1.1697 | Enterprise Value | Enterprise Value Ebitda 10.4183 | Price Sales 0.0132 | Forward PE 12.7714 |
Fairly Valued
Today
Please note that Takeda Pharmaceutical's price fluctuation is very steady at this time. Calculation of the real value of Takeda Pharmaceutical is based on 3 months time horizon. Increasing Takeda Pharmaceutical's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Takeda Pharmaceutical's intrinsic value may or may not be the same as its current market price of 18.66, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 18.66 | Real 18.21 | Target 18.86 | Hype 18.69 | Naive 18.73 |
The intrinsic value of Takeda Pharmaceutical's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Takeda Pharmaceutical's stock price.
Estimating the potential upside or downside of Takeda Pharmaceutical Co helps investors to forecast how Takeda stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Takeda Pharmaceutical more accurately as focusing exclusively on Takeda Pharmaceutical's fundamentals will not take into account other important factors: Takeda Pharmaceutical Cash |
|
Takeda Pharmaceutical Total Value Analysis
Takeda Pharmaceutical Co is at this time forecasted to have company total value of 84.78 B with market capitalization of 58.95 B, debt of 4.52 T, and cash on hands of 233.74 B. Please note that company total value may be misleading and is a subject to accounting gimmicks. We encourage investors to carefully check all of the Takeda Pharmaceutical fundamentals before making security assessment based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
84.78 B | 58.95 B | 4.52 T | 233.74 B |
Takeda Pharmaceutical Investor Information
The company has price-to-book ratio of 1.17. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Takeda Pharmaceutical has Price/Earnings To Growth (PEG) ratio of 0.4. The entity last dividend was issued on the 30th of September 2025. Takeda Pharmaceutical Co is not in a good financial situation at this time. It has a very high probability of going through financial hardship in March.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Operating Profit Margin | 0.21 | 0.16 |
|
| |||||
| Total Cash From Operating Activities | 1.3 T | 1.2 T |
|
|
Takeda Pharmaceutical Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Takeda Pharmaceutical has an asset utilization ratio of 32.15 percent. This suggests that the Company is making $0.32 for each dollar of assets. An increasing asset utilization means that Takeda Pharmaceutical Co is more efficient with each dollar of assets it utilizes for everyday operations.Takeda Pharmaceutical Profitability Analysis
Taking into consideration Takeda Pharmaceutical's profitability measurements, Takeda Pharmaceutical's profitability may be sliding down. It has an above-average probability of reporting lower numbers next quarter. Profitability indicators assess Takeda Pharmaceutical's ability to earn profits and add value for shareholders.Net Income | First Reported 2008-09-30 | Previous Quarter -11.8 B | Current Value 105.5 B | Quarterly Volatility 62.9 B |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.73 | 0.62 |
|
| |||||
| Operating Profit Margin | 0.21 | 0.16 |
|
|
For Takeda Pharmaceutical profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Takeda Pharmaceutical to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Takeda Pharmaceutical utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Takeda Pharmaceutical's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Takeda Pharmaceutical over time as well as its relative position and ranking within its peers.
Takeda Pharmaceutical Earnings per Share Projection vs Actual
The next projected EPS of Takeda Pharmaceutical is estimated to be 12.3015 with future projections ranging from a low of 12.3015 to a high of 12.3015. Takeda Pharmaceutical's most recent 12-month trailing earnings per share (EPS TTM) is at 0.23. Please be aware that the consensus of earnings estimates for Takeda Pharmaceutical Co is based on EPS before non-recurring items and includes expenses related to employee stock options.Takeda Pharmaceutical Earnings Estimation Breakdown
The calculation of Takeda Pharmaceutical's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Takeda Pharmaceutical is estimated to be 12.3015 with the future projection ranging from a low of 12.3015 to a high of 12.3015. Please be aware that this consensus of annual earnings estimates for Takeda Pharmaceutical Co is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
12.30 Lowest | Expected EPS | 12.30 Highest |
Takeda Pharmaceutical Earnings Projection Consensus
Suppose the current estimates of Takeda Pharmaceutical's value are higher than the current market price of the Takeda Pharmaceutical stock. In this case, investors may conclude that Takeda Pharmaceutical is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Takeda Pharmaceutical's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2026 | Current EPS (TTM) | |
| 3 | 25.36% | -0.2276 | 12.3015 | 0.23 |
Takeda Pharmaceutical Ownership Allocation
Takeda Pharmaceutical shows a total of 3.16 Billion outstanding shares. About 97.3 % of Takeda Pharmaceutical outstanding shares are held by general public with 2.7 % by institutional holders. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Takeda Pharmaceutical Profitability Analysis
The company reported the last year's revenue of 4.58 T. Total Income to common stockholders was 107.93 B with profit before taxes, overhead, and interest of 2.93 T.Takeda Pharmaceutical Past Distributions to stockholders
About Takeda Pharmaceutical Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Takeda Pharmaceutical Co. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Takeda Pharmaceutical based exclusively on its fundamental and basic technical indicators. By analyzing Takeda Pharmaceutical's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Takeda Pharmaceutical's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Takeda Pharmaceutical. We calculate exposure to Takeda Pharmaceutical's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Takeda Pharmaceutical's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 3.5 T | 3.6 T | |
| Pretax Profit Margin | 0.04 | 0.04 | |
| Operating Profit Margin | 0.16 | 0.21 | |
| Net Profit Margin | 0.03 | 0.03 | |
| Gross Profit Margin | 0.62 | 0.73 |
Takeda Pharmaceutical Quarterly Retained Earnings |
|
A single share of Takeda Pharmaceutical represents a small ownership stake in the entity. As a stockholder of Takeda, your percentage of company ownership is determined by dividing the number of shares you own by the total number of shares outstanding and then multiplying that amount by 100. Owning stock in a company generally confers both corporate voting rights and income from any dividends paid to the stock owner.
Takeda Pharmaceutical Dividends Analysis For Valuation
At this time, Takeda Pharmaceutical's Dividends Paid is quite stable compared to the past year. Dividend Payout Ratio is expected to rise to 2.65 this year, although the value of Dividend Yield will most likely fall to 0.03. . At this time, Takeda Pharmaceutical's Retained Earnings are quite stable compared to the past year. Price Earnings Ratio is expected to rise to 61.01 this year, although the value of Earnings Yield will most likely fall to 0.02.
| Last Reported | Projected for Next Year | ||
| Dividends Paid | 347.9 B | 365.3 B | |
| Dividend Yield | 0.04 | 0.03 | |
| Dividend Payout Ratio | 2.52 | 2.65 | |
| Dividend Paid And Capex Coverage Ratio | 2.20 | 2.07 |
There are various types of dividends Takeda Pharmaceutical can pay to its shareholders, and the actual value of the dividend is determined on a per-share basis. It is to be paid equally to all of Takeda shareholders on a specific date, known as the payable date. The cash dividend is the most common type of dividend payment - it is the payment of actual cash from Takeda Pharmaceutical Co directly to its shareholders. There are other types of dividends that companies can issue, such as stock dividends or asset dividends. When Takeda pays a dividend, it has no impact on its enterprise value. It does, however, lowers the Equity Value of Takeda Pharmaceutical by the value of the dividends paid out.
Takeda Pharmaceutical Growth Indicators
Investing in growth stocks can be very risky. If the company such as Takeda Pharmaceutical does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 3.2 B | |
| Quarterly Earnings Growth Y O Y | 3.302 | |
| Forward Price Earnings | 12.7714 |
Takeda Pharmaceutical Current Valuation Indicators
Takeda Pharmaceutical's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Takeda Pharmaceutical's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Takeda Pharmaceutical, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Takeda Pharmaceutical's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Takeda Pharmaceutical's worth.When determining whether Takeda Pharmaceutical is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Takeda Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Takeda Pharmaceutical Co Stock. Highlighted below are key reports to facilitate an investment decision about Takeda Pharmaceutical Co Stock: Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Takeda Pharmaceutical Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Takeda Pharmaceutical. If investors know Takeda will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Takeda Pharmaceutical assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 3.302 | Dividend Share 198 | Earnings Share 0.23 | Revenue Per Share | Quarterly Revenue Growth 0.042 |
The market value of Takeda Pharmaceutical is measured differently than its book value, which is the value of Takeda that is recorded on the company's balance sheet. Investors also form their own opinion of Takeda Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Takeda Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Takeda Pharmaceutical's market value can be influenced by many factors that don't directly affect Takeda Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Takeda Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Takeda Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Takeda Pharmaceutical's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.